All In Biotech

Drug Trial Radar · NCT02775617

Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology

Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,291 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,291

Actual

Start

Jul 2016

Primary completion

Aug 2017

Study completion Feb 5, 2018

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Atoifi Adventist Hospital, Solomon Islands; Kirby Institute; Murdoch Childrens Research Institute
First posted
May 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections. Communities will be randomised to receive standard treatment for both yaws and scabies either in parallel (site 1) or in sequence (site 2). Treatment of yaws: Single dose of Azithromycin (30mg/kg, max 2G). Treatment of scabies: Either an oral dose of Ivermectin (200μg/kg) or permethrin cream for those with a contraindication to Ivermectin (WT\<15kg, pregnant or breastfeeding women) given in 2 doses 7-14 days apart. Investigators will complete a clinical and microbiological assessment of bacterial skin disease at baseline and at 12 months to assess the impact of treatment on the prevalence of bacterial infection and the emergence of antimicrobial resistance. Primary Outcome 1. Difference in the change in prevalence of impetigo between baseline and 12- months between the parallel and the sequential treatment arms. Secondary Outcomes 2. Change in the proportion of swab samples from which S. pyogenes is cultured between baseline and follow-up in the two arms 3. The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured in the two arms

Conditions

  • Scabies
  • Yaws
  • Impetigo

Interventions

  • IvermectinDrug

    Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.

  • AzithromycinDrug

    Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.

  • PermethrinDrug

    Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Impetigo Prevalence at 12 MonthsTime frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atoifi Adventist Hospital

    Atoifi, Malaita Province, Solomon Islands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.